These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 25062862)

  • 1. The potential of composite cognitive scores for tracking progression in Huntington's disease.
    Jones R; Stout JC; Labuschagne I; Say M; Justo D; Coleman A; Dumas EM; Hart E; Owen G; Durr A; Leavitt BR; Roos R; O'Regan A; Langbehn D; Tabrizi SJ; Frost C
    J Huntingtons Dis; 2014; 3(2):197-207. PubMed ID: 25062862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.
    Tabrizi SJ; Reilmann R; Roos RA; Durr A; Leavitt B; Owen G; Jones R; Johnson H; Craufurd D; Hicks SL; Kennard C; Landwehrmeyer B; Stout JC; Borowsky B; Scahill RI; Frost C; Langbehn DR;
    Lancet Neurol; 2012 Jan; 11(1):42-53. PubMed ID: 22137354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.
    Tabrizi SJ; Scahill RI; Owen G; Durr A; Leavitt BR; Roos RA; Borowsky B; Landwehrmeyer B; Frost C; Johnson H; Craufurd D; Reilmann R; Stout JC; Langbehn DR;
    Lancet Neurol; 2013 Jul; 12(7):637-49. PubMed ID: 23664844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognition in Huntington's disease in manifest, premanifest and converting gene carriers over ten years.
    Hart EP; Dumas EM; Giltay EJ; Middelkoop HA; Roos RA
    J Huntingtons Dis; 2013; 2(2):137-47. PubMed ID: 25063511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HD-CAB: a cognitive assessment battery for clinical trials in Huntington's disease 1,2,3.
    Stout JC; Queller S; Baker KN; Cowlishaw S; Sampaio C; Fitzer-Attas C; Borowsky B;
    Mov Disord; 2014 Sep; 29(10):1281-8. PubMed ID: 25209258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis.
    Tabrizi SJ; Scahill RI; Durr A; Roos RA; Leavitt BR; Jones R; Landwehrmeyer GB; Fox NC; Johnson H; Hicks SL; Kennard C; Craufurd D; Frost C; Langbehn DR; Reilmann R; Stout JC;
    Lancet Neurol; 2011 Jan; 10(1):31-42. PubMed ID: 21130037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rate of change in early Huntington's disease: a clinicometric analysis.
    Meyer C; Landwehrmeyer B; Schwenke C; Doble A; Orth M; Ludolph AC;
    Mov Disord; 2012 Jan; 27(1):118-24. PubMed ID: 22095693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease.
    Stout JC; Jones R; Labuschagne I; O'Regan AM; Say MJ; Dumas EM; Queller S; Justo D; Santos RD; Coleman A; Hart EP; Dürr A; Leavitt BR; Roos RA; Langbehn DR; Tabrizi SJ; Frost C
    J Neurol Neurosurg Psychiatry; 2012 Jul; 83(7):687-94. PubMed ID: 22566599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Motor dysfunction influence on executive functioning in manifest and premanifest Huntington's disease.
    Hart EP; Dumas EM; Schoonderbeek A; Wolthuis SC; van Zwet EW; Roos RA
    Mov Disord; 2014 Mar; 29(3):320-6. PubMed ID: 24500841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal change in white matter microstructure in Huntington's disease: The IMAGE-HD study.
    Poudel GR; Stout JC; Domínguez D JF; Churchyard A; Chua P; Egan GF; Georgiou-Karistianis N
    Neurobiol Dis; 2015 Feb; 74():406-12. PubMed ID: 25497085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing impairment of executive function and psychomotor speed in premanifest and manifest Huntington's disease gene-expansion carriers.
    Unmack Larsen I; Vinther-Jensen T; Gade A; Nielsen JE; Vogel A
    J Int Neuropsychol Soc; 2015 Mar; 21(3):193-202. PubMed ID: 25850430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. White matter connectivity reflects clinical and cognitive status in Huntington's disease.
    Poudel GR; Stout JC; Domínguez D JF; Salmon L; Churchyard A; Chua P; Georgiou-Karistianis N; Egan GF
    Neurobiol Dis; 2014 May; 65():180-7. PubMed ID: 24480090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression of motor subtypes in Huntington's disease: a 6-year follow-up study.
    Jacobs M; Hart EP; van Zwet EW; Bentivoglio AR; Burgunder JM; Craufurd D; Reilmann R; Saft C; Roos RA;
    J Neurol; 2016 Oct; 263(10):2080-5. PubMed ID: 27435968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tongue force analysis assesses motor phenotype in premanifest and symptomatic Huntington's disease.
    Reilmann R; Bohlen S; Klopstock T; Bender A; Weindl A; Saemann P; Auer DP; Ringelstein EB; Lange HW
    Mov Disord; 2010 Oct; 25(13):2195-202. PubMed ID: 20645403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver function in Huntington's disease assessed by blood biochemical analyses in a clinical setting.
    Nielsen SM; Vinther-Jensen T; Nielsen JE; Nørremølle A; Hasholt L; Hjermind LE; Josefsen K
    J Neurol Sci; 2016 Mar; 362():326-32. PubMed ID: 26944172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypokinesia in Huntington's disease co-occurs with cognitive and global dysfunctioning.
    Reedeker N; Van Der Mast RC; Giltay EJ; Van Duijn E; Roos RA
    Mov Disord; 2010 Aug; 25(11):1612-8. PubMed ID: 20629165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validity of the Montreal Cognitive Assessment in the detection of cognitive dysfunction in Huntington's disease.
    Bezdicek O; Majerova V; Novak M; Nikolai T; Ruzicka E; Roth J
    Appl Neuropsychol Adult; 2013; 20(1):33-40. PubMed ID: 23373682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study.
    Moss DJH; Pardiñas AF; Langbehn D; Lo K; Leavitt BR; Roos R; Durr A; Mead S; ; ; Holmans P; Jones L; Tabrizi SJ
    Lancet Neurol; 2017 Sep; 16(9):701-711. PubMed ID: 28642124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life in Huntington's disease: a comparative study investigating the impact for those with pre-manifest and early manifest disease, and their partners.
    Read J; Jones R; Owen G; Leavitt BR; Coleman A; Roos RA; Dumas EM; Durr A; Justo D; Say M; Stout JC; Tabrizi SJ; Craufurd D;
    J Huntingtons Dis; 2013; 2(2):159-75. PubMed ID: 25063513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in cognitive control in pre-manifest Huntington's disease examined using pre-saccadic EEG potentials - a longitudinal study.
    Ness V; Bestgen AK; Saft C; Beste C
    J Huntingtons Dis; 2014; 3(1):33-43. PubMed ID: 25062763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.